COO

Business profile & competitive position

The Cooper Companies, Inc. (COO) sits in the Healthcare sector, specifically the Medical – Instruments & Supplies industry. It is a global medical device company that runs two distinct units. CooperVision develops, manufactures and markets single-use, two-week and monthly contact lenses, including silicone hydrogel lenses, myopia-management products such as MiSight 1 day, orthokeratology lenses and scleral lenses. CooperSurgical supplies more than 600 products and services in fertility and women’s health, covering gynecology, obstetrics, contraception, labor and delivery, cord-blood and tissue storage, IVF support, donor gametes, cryopreservation and genomic services. Products are sold in over 130 countries, and the company states that its products positively impact more than fifty million lives each year. MiSight 1 day is the only contact lens approved by the FDA, China’s NMPA and Japan’s MHLW to slow the progression of, and correct, myopia in age-appropriate children. The company employs roughly 500 people in research and development across both segments.

What do the financial returns say about competitive positioning? Net margin is 13.5%, which is respectable for a medical-device business with recurring replacement demand, and it points to some pricing power and manufacturing scale. Return on equity, however, is only 6.9%. A mid-single-digit ROE is modest relative to top-tier healthcare franchises and can signal capital intensity, acquisition-related goodwill, or lower asset turnover. Beta is 0.82, below the market average, consistent with a business built on consumable products such as contact lenses and fertility supplies rather than cyclical equipment sales. The picture is one of a stable, regulated consumables company with decent margins but not an unusually wide moat in ROE terms.

Financial posture

COO’s current market capitalization is $10.8 billion and the stock trades at roughly $55.49. The trailing P/E ratio is 18.9. For a large-cap healthcare company, that is a moderate multiple rather than a deep-value or hyper-growth valuation. Net margin of 13.5% supports earnings, yet ROE of 6.9% means equity capital is not generating premium returns. A beta of 0.82 suggests lower volatility than the broad market, which fits the defensive, recurring-revenue character of contact lenses and women’s-health consumables.

Technically, the stock is under near-term pressure: the current price of $55.49 is below the 50-day exponential moving average of $61.73, and the RSI is 37.6—near traditionally oversold territory. The valuation multiple of 18.9x, combined with a 13.5% net margin, frames COO as a profitable healthcare name trading at a discount to its own recent trendline rather than a speculative position.

Strategic priorities & outlook

The company’s most recent 10-K filing outlines a strategy built on penetration and tuck-in expansion rather than dramatic product pivots. At CooperVision, priorities include greater worldwide market penetration of recently introduced products, expanding presence in existing and emerging markets, and increasing investment in distribution and packaging capabilities to support growth and service levels. CooperVision is also investing to develop the myopia-management market by educating eye care practitioners, patients and their families. At CooperSurgical, management expects to continue investing in the business, including through strategic transactions, to expand its integrated solutions model within fertility and women’s health.

In plain terms, the near-term playbook is volume-led—push recently launched lenses harder internationally, build out distribution infrastructure, teach the market about myopia management, and bolt on acquisitions in fertility and women’s health. That plan leans on execution and geographic reach, not on a single blockbuster pipeline event.

Macro & geopolitical exposure

Because COO is classified as Medical – Instruments & Supplies, the stock carries the macro profile typical of that industry. Regulatory exposure is substantial: contact lenses and women’s-health devices must win and maintain approvals from bodies such as the FDA, China’s NMPA and Japan’s MHLW. Any delay or labeling change can alter growth trajectories. With sales in over 130 countries, currency translation and local pricing matter; a stronger U.S. dollar pressures reported revenue, while weaker foreign currencies pressure margins. Supply-chain risks include sourcing of specialized polymers, packaging materials and components used in silicone hydrogel lenses, plus cold-chain logistics for cryopreservation and donor-gamete products in fertility services.

Demand-side drivers are partly demographic: rising myopia prevalence supports CooperVision, and fertility trends and women’s-health awareness support CooperSurgical. On the downside, contact lenses sit at the intersection of healthcare and consumer spending, so household-budget pressure can affect wear schedules and premium-lens uptake. Reimbursement changes, tariffs on medical-device imports, and cross-border trade policy also sit in the background for instruments-and-supplies companies with global manufacturing footprints.

Recent developments

Recent headlines have centered on legal attention rather than product launches. On October 9, 2026, October 10, 2026, and October 11, 2026, Newsfile published repeated notices from ROSEN, a plaintiffs’ securities law firm, encouraging investors to inquire about a securities class-action investigation involving The Cooper Companies (COO). These are attorney announcements, not filed or adjudicated claims, but the clustering of three consecutive days of such notices can elevate options activity and short-term volatility around the name.

On October 9, 2026, Zacks published “Why Is The Cooper Companies (COO) Up 0.2% Since Last Earnings Report?” That small positive footprint since the September 9 report underscores how little a headline EPS beat can matter when the market is focused on guidance, margins or legal overhang.

Earnings behavior & post-earnings drift

COO’s earnings track record looks perfect on the surface but more complicated underneath. Over the last eight reported quarters, the company beat the consensus EPS estimate every time—an 8/8, or 100%, beat rate—with an average earnings surprise of 4.2%. Nevertheless, the average 5-day price move in the trading sessions after those reports was −2.34%, classified as a down post-earnings drift. That is the central puzzle: beating estimates has not reliably produced a sustained rally.

The most recent four quarters are a vivid illustration:

• September 9, 2026: actual EPS $1.15 vs. estimate $1.12, a 2.7% beat. The stock fell 14.67% the next day and 13.97% over the following five days.
• June 4, 2026: actual EPS $1.21 vs. estimate $1.10, a 10.0% beat. The stock rose 8.58% the next day and 8.85% over the next five days.
• March 5, 2026: actual EPS $1.10 vs. estimate $1.03, a 6.8% beat. The stock fell 4.55% the next day and 10.82% over the next five days.
• December 4, 2025: actual EPS $1.15 vs. estimate $1.11, a 3.6% beat. The stock rose 5.67% the next day and 6.59% over the next five days.

The pattern is not “beat and pop.” The September 2026 quarter, in particular, shows that a positive surprise can be overwhelmed by forward guidance, margin commentary, or the broader discount the market applies around the report. With the next scheduled earnings release set for December 3, 2026, after the close, the consensus EPS estimate is $1.07. The current price of $55.49, RSI of 37.6 and 50-day EMA of $61.73 suggest investors entering the event are doing so in a technically weak tape. The real lesson is that the market’s real expectation often sits beyond the headline number—in guidance, segment commentary, and valuation adjustment.

For a deeper look at how institutional analysts and models are weighing COO’s earnings setup, valuation and forward estimates, readers should review the full institutional verdict on the ticker.